CLENE INC (CLNN) Stock Price & Overview
NASDAQ:CLNN • US1856342019
Current stock price
The current stock price of CLNN is 5.12 USD. Today CLNN is up by 4.7%. In the past month the price decreased by -3.4%. In the past year, price increased by 90.33%.
CLNN Key Statistics
- Market Cap
- 55.552M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.60
- Dividend Yield
- N/A
CLNN Stock Performance
CLNN Stock Chart
CLNN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CLNN. When comparing the yearly performance of all stocks, CLNN is one of the better performing stocks in the market, outperforming 86.5% of all stocks.
CLNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLNN. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative.
CLNN Earnings
On March 12, 2026 CLNN reported an EPS of -0.88 and a revenue of 77.00K. The company missed EPS expectations (-47.23% surprise) and beat revenue expectations (108.25% surprise).
CLNN Forecast & Estimates
12 analysts have analysed CLNN and the average price target is 30.94 USD. This implies a price increase of 504.3% is expected in the next year compared to the current price of 5.12.
For the next year, analysts expect an EPS growth of 18.4% and a revenue growth 43.04% for CLNN
CLNN Groups
Sector & Classification
CLNN Financial Highlights
Over the last trailing twelve months CLNN reported a non-GAAP Earnings per Share(EPS) of -2.6. The EPS increased by 56.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLNN Ownership
CLNN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLNN
Company Profile
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Company Info
IPO: 2018-08-27
CLENE INC
6550 South Millrock Drive, Suite G50
Salt Lake City UTAH 84121 US
CEO: Robert Etherington
Employees: 76
Phone: 18016769695
CLENE INC / CLNN FAQ
What does CLNN do?
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2018-08-27. The company specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
What is the stock price of CLENE INC today?
The current stock price of CLNN is 5.12 USD. The price increased by 4.7% in the last trading session.
Does CLENE INC pay dividends?
CLNN does not pay a dividend.
How is the ChartMill rating for CLENE INC?
CLNN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of CLENE INC (CLNN)?
CLENE INC (CLNN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.6).
Who owns CLENE INC?
You can find the ownership structure of CLENE INC (CLNN) on the Ownership tab.
What is the outstanding short interest for CLENE INC?
The outstanding short interest for CLENE INC (CLNN) is 11.09% of its float.